CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
Clinical trial NCT03566446 · COMPLETED
Trial details
- NCT number
- NCT03566446
- Sponsor
- Inge Marie Svane
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-20
- Primary completion
- 2020-02-20
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.